(2S)-2-amino-3-[4-(difluoromethoxy)phenyl]propanoic acid

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: (2S)-2-amino-3-[4-(difluoromethoxy)phenyl]propanoic acid
• 化学式: C₁₀H₁₁F₂NO₃
• mdl: MFCD11858222
• 分子量: 231.2
• InChiKey: ITFQXKAULLPDSW-QMMMGPOBSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.2
• 重原子数：
  16
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  77
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  氟里昂-22 生成 (2S)-2-amino-3-[4-(difluoromethoxy)phenyl]propanoic acid
  参考文献：
  名称：

  KOLYCHEVA, M. T.;GERUS, I. I.;YAGUPOLSKIJ, YU. L.;KUXAR, V. P., 6-AYA BCEC. KONF. PO XIMII FTORORGAN. SOED., , 26-28 IYUNYA,+

  摘要：

  DOI：

文献信息

• [EN] PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY DISEASES<br/>[FR] INHIBITEURS PEPTIDIQUES DU RÉCEPTEUR DE L'INTERLEUKINE-23 ET LEUR UTILISATION POUR TRAITER DES MALADIES INFLAMMATOIRES
  申请人：PROTAGONIST THERAPEUTICS INC

  公开号：WO2021146458A1

  公开（公告）日：2021-07-22

  The present invention provides novel peptide inhibitors of the interleukin-23 receptor, and related compositions and methods of using these peptide inhibitors to treat or prevent a variety of diseases and disorders, including inflammatory bowel diseases.

  本发明提供了新型肽抑制剂，用于干扰白细胞介素-23受体，并提供了相关的组合物和方法，用于治疗或预防多种疾病和紊乱，包括炎症性肠病。
• SUBSTITUTED PROPANAMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME
  申请人：Daiichi Sankyo Company, Limited

  公开号：EP1908466B1

  公开（公告）日：2014-02-19
• KOLYCHEVA, M. T.;GERUS, I. I.;YAGUPOLSKIJ, YU. L.;GALUSHKO, S. V.;KUXAR, +, ZH. ORGAN. XIMII, 27,(1991) N, S. 781-788
  作者：KOLYCHEVA, M. T.、GERUS, I. I.、YAGUPOLSKIJ, YU. L.、GALUSHKO, S. V.、KUXAR, +

  DOI：——

  日期：——
• CYCLIC PEPTIDE COMPOUND HAVING HIGH MEMBRANE PERMEABILITY, AND LIBRARY CONTAINING SAME
  申请人：Chugai Seiyaku Kabushiki Kaisha

  公开号：US20200131669A1

  公开（公告）日：2020-04-30

  The present inventors have found that when screening for cyclic peptide compounds that can specifically bind to a target molecule, the use of a library including cyclic peptide compounds having a long side chain in the cyclic portion can improve the hit rate for cyclic peptide compounds that can specifically bind to the target molecule. Meanwhile, the present inventors have found that tryptophan and tyrosine residues, which have conventionally been used in oral low molecular-weight pharmaceuticals and are amino acid residues having an indole skeleton or a hydroxyphenyl group, are not suitable for peptides intended to attain high membrane permeability.
• US8344029B2
  申请人：——

  公开号：US8344029B2

  公开（公告）日：2013-01-01